es its liquid
assets principally to cover research and development expenses, expenses
relating to the development of relationships with pharmaceutical companies,
with a view to encouraging new partnerships, and corporate expenses related
to general and administrative and promotional activities. NicOx expects its
operating expenses to continue to increase very strongly over the coming
financial years, as a result of the anticipated expenses related to the
clinical development and the launch preparation activities for its drug
candidate naproxcinod, which is currently in phase 3 clinical development.
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven
biopharmaceutical company dedicated to the development and future
commercialization of investigational drugs for unmet medical needs. NicOx
is applying its proprietary nitric oxide-donating technology to develop an
internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas
of inflammatory and cardio-metabolic disease.
Resources are focused on the development of naproxcinod, a proprietary
NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric
Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase
3 clinical studies for the treatment of the signs and symptoms of
osteoarthritis, with final phase 3 results anticipated in 2008.
Beyond naproxcinod, NicOx has a pipeline containing multiple nitric
oxide-donating NCEs, which are in development internally and with partners,
including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent
and underserved diseases, such as atherosclerosis, hypertension, widespread
eye diseases and Chronic Obstructive Pulmonary Disease (COPD).
NicOx S.A. is headquartered in France and is listed on the Euronext
Paris Stock Exchange (Compartment B: Mid Caps).
This press release contains certain forward-looking statements.
Although the Company believes its expectations are based on reasonable
assumPage: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1
. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules2
. NicOx Announces Departure of Damian Marron for CEO Position3
. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance4
. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis5
. NicOx to Present at Financial Conferences in New York on November 27, 28 and 296
. NicOx Opens U.S. Headquarters in New Jersey7
. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months8
. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.9
. Amylin Pharmaceuticals Reports Third Quarter Financial Results10
. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer11
. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing